Paper Details

  1. Home
  2. Paper Details

[Interaction of sulfinpyrazone (Anturan) and glibenclamide (Euglucon) in type II diabetic patients].

Author: IrsiglerK, KritzH, NajemnikC

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Sulfinpyrazone did not interact with glibenclamide in well-controlled type II diabetics. The treatment was well tolerated and no side effects were observed.
Paper Details　
Original Abstract of the Article :
In a randomised double blind study on 19 with glibenclamide well controlled diabetics of type II the possible interaction between sulfinpyrazone (Anturan) and glibenclamide was studied with the help of the artificial endocrine pancreas. The trial substance in a dose of 800 mg/die or placebo were use...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/6408808

データ提供：米国国立医学図書館（NLM）

Sulfinpyrazone and Glibenclamide: A Case of No Interaction

The field of diabetes management is continually seeking ways to optimize treatment strategies. This study investigated a potential interaction between sulfinpyrazone, a drug used to treat gout, and glibenclamide, a medication for type II diabetes. The researchers conducted a double-blind study to determine if these two drugs affect each other's efficacy in controlling blood sugar levels. Their findings have important implications for patients taking both medications.

No Evidence of Interaction: A Relief for Patients

The researchers found no evidence of interaction between sulfinpyrazone and glibenclamide in type II diabetic patients. This means that patients taking both medications can do so safely and effectively without worrying about one drug interfering with the other's action. This study provides reassurance to patients and healthcare providers alike.

Managing Diabetes with Confidence: A Clear Path

This research offers valuable information for patients with type II diabetes who are also being treated for gout. The finding of no interaction between sulfinpyrazone and glibenclamide eliminates a potential concern and allows for more confident management of these conditions. As always, regular monitoring and communication with your healthcare provider are crucial for optimal health outcomes.

Dr.Camel's Conclusion

This study is like a camel caravan encountering a clear path through the desert. It dispels the notion of an interaction between sulfinpyrazone and glibenclamide, giving patients and physicians a clear path for managing both gout and type II diabetes.

Date :
  1. Date Completed 1983-08-26
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

6408808

DOI: Digital Object Identifier

6408808

Related Literature

Article Analysis
・Side Effects of sulfinpyrazone
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.